

# Zeljko Reiner

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4756874/zeljko-reiner-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

195  
papers

44,994  
citations

60  
h-index

212  
g-index

223  
ext. papers

53,273  
ext. citations

4.7  
avg, IF

6.76  
L-index

#	Paper	IF	Citations
195	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , <b>2012</b> , 33, 2569-619	9.5	3978
194	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , <b>2012</b> , 33, 1787-847	9.5	3691
193	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2013</b> , 34, 2159-219	9.5	3400
192	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , <b>2012</b> , 33, 2451-96	9.5	2866
191	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , <b>2012</b> , 33, 1482-1501	9.5	2797
190	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , <b>2012</b> , 33, 2719-47	9.5	2638
189	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 111-188	9.5	2236
188	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 1581-98	15.1	2143
187	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , <b>2011</b> , 32, 1769-818	9.5	2020
186	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 803-69	12.3	1892
185	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , <b>2016</b> , 37, 2999-3058	9.5	1781
184	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , <b>2019</b> , 40, 3035-87	9.5	1444
183	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2011</b> , 32, 2851-906	9.5	1126
182	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , <b>2010</b> , 31, 2844-53	9.5	1100
181	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , <b>2007</b> , 28, 3235-114	9.5	1029
180	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , <b>2011</b> , 32, 1345-61	9.5	793
179	European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2007</b> , 14 Suppl 2, S1-113		751

178	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 636-48	3.9	549
177	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association of Cardiovascular Prevention and Rehabilitation (EACVPR). <i>Atherosclerosis</i> , <b>2016</b> , 253, 231-344	3.1	519
176	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , <b>2011</b> , 217, 3-46	3.1	459
175	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , <b>2012</b> , 33, 2453-2496		309
174	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 824-835	3.9	288
173	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>Atherosclerosis</i> , <b>2012</b> , 233, 1-46	3.1	286
172	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 1K-34K	3	280
171	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , <b>2014</b> , 35, 960-8	9.5	222
170	European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>International Journal of Behavioral Medicine</i> , <b>2012</b> , 19, 403-88	2.6	196
169	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. <i>Diabetes and Vascular Disease Research</i> , <b>2008</b> , 5, 319-35	3.3	192
168	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. <i>Atherosclerosis</i> , <b>2007</b> , 194, 1-45	3.1	190
167	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , <b>2017</b> , 75, 731-767	6.4	186
166	Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. <i>Atherosclerosis</i> , <b>2014</b> , 235, 21-30	3.1	181
165	Hypertriglyceridaemia and risk of coronary artery disease. <i>Nature Reviews Cardiology</i> , <b>2017</b> , 14, 401-411	14.8	178
164	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , <b>2017</b> , 13, 965-1005	2.9	173
163	Statins and the COVID-19 main protease: evidence on direct interaction. <i>Archives of Medical Science</i> , <b>2020</b> , 16, 490-496	2.9	164
162	The Role of Nutraceuticals in Statin Intolerant Patients. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 96-118	15.1	157
161	EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2010</b> , 17, 530-40		155

160	Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. <i>Circulation</i> , <b>2014</b> , 129, 999-1008	16.7	153
159	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , <b>2011</b> , 217 Suppl 1, S1-44	3.1	152
158	Resistance and intolerance to statins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2014</b> , 24, 1057-66	14.8	132
157	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. <i>Atherosclerosis</i> , <b>2016</b> , 246, 243-50	3.1	121
156	Statins in the primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 453-64	14.8	119
155	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , <b>2015</b> , 241, 169-75	3.1	114
154	Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 1107-9	3	110
153	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , <b>2019</b> , 285, 135-146	3.1	106
152	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 1K-34K	3	98
151	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 2007-2018	3.9	96
150	Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. <i>Atherosclerosis</i> , <b>2010</b> , 213, 598-603	3.1	93
149	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , <b>2018</b> , 277, 234-255	3.1	93
148	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , <b>2017</b> , 33, 1-5	3.5	88
147	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2013</b> , 23, 799-807	4.5	85
146	Management of patients with familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , <b>2015</b> , 12, 565-74	14.8	79
145	Adverse effects of statins - myths and reality. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 1220-6	3.3	78
144	Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A311-A311	0.4	78
143	Population-level changes to promote cardiovascular health. <i>European Journal of Preventive Cardiology</i> , <b>2013</b> , 20, 409-21	3.9	76

142	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 133	8.7	74
141	Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 1641-8	1.9	74
140	Dyslipidemias in the prevention of cardiovascular disease: risks and causality. <i>Current Cardiology Reports</i> , <b>2012</b> , 14, 709-20	4.2	71
139	Combined therapy in the treatment of dyslipidemia. <i>Fundamental and Clinical Pharmacology</i> , <b>2010</b> , 24, 19-28	3.1	70
138	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". <i>Atherosclerosis</i> , <b>2018</b> , 275, 265-272	3.1	69
137	The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Food and Function</i> , <b>2019</b> , 10, 6042-6051	6.1	65
136	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 71	8.7	64
135	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 1354-62	3.9	60
134	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , <b>2016</b> , 22, 1-32	1.7	60
133	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , <b>2016</b> , 209, 284-90	3.2	57
132	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , <b>2016</b> , 18, C2-C12	1.5	56
131	The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1300	5.6	55
130	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , <b>2019</b> , 143, 1-16	10.2	54
129	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , <b>2015</b> , 19, 1-12	1.7	50
128	Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. <i>Pharmacological Research</i> , <b>2017</b> , 122, 53-65	10.2	49
127	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , <b>2013</b> , 231, 300-7	3.1	49
126	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 1664-1678	12.7	45
125	Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. <i>Preventive Medicine</i> , <b>2010</b> , 51, 494-6	4.3	43

124	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , <b>2020</b> , 158, 104891	10.2	42
123	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , <b>2019</b> , 140, 2054-2062	16.7	41
122	Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. <i>European Heart Journal</i> , <b>2012</b> , 33, 2865-72	9.5	41
121	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 160-8	3.2	39
120	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , <b>2016</b> , 76, 947-56	12.1	38
119	Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. <i>Clinical Drug Investigation</i> , <b>2005</b> , 25, 701-7	3.2	37
118	Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. <i>European Heart Journal</i> , <b>2014</b> , 35, 590-8	9.5	36
117	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 1383-1401	3.9	32
116	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1202-10	3.9	32
115	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , <b>2018</b> , 50, 565-575	1.5	29
114	Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 1212-9	3.9	28
113	Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2006</b> , 13, 646-54		28
112	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , <b>2012</b> , 65, 938.e1-938.e59	1.5	27
111	Management of overweight and obese patients with coronary heart disease across Europe. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2010</b> , 17, 447-54		27
110	The burden of hyperlipidaemia and diabetes in cardiovascular diseases. <i>Fundamental and Clinical Pharmacology</i> , <b>2007</b> , 21 Suppl 2, 1-3	3.1	26
109	Prevalence and types of persistent dyslipidemia in patients treated with statins. <i>Croatian Medical Journal</i> , <b>2013</b> , 54, 339-45	1.6	25
108	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320908698	3.9	25
107	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 162-71	7	24



106	Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. <i>Fundamental and Clinical Pharmacology</i> , <b>2012</b> , 26, 163-74	3.1	24
105	The perception and knowledge of cardiovascular risk factors among medical students. <i>Croatian Medical Journal</i> , <b>2012</b> , 53, 278-84	1.6	23
104	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , <b>2021</b> , 325, 99-109	3.1	22
103	Improvement of endothelial function by pitavastatin: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 279-286	4	21
102	PCSK9 and infection: A potentially useful or dangerous association?. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 2920-2927	7	21
101	Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. <i>Croatian Medical Journal</i> , <b>2011</b> , 52, 566-75	1.6	21
100	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , <b>2020</b> , 33, 155-179	7	20
99	Educational level and risk profile and risk control in patients with coronary heart disease. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 881-90	3.9	20
98	Primary prevention of cardiovascular disease with statins in the elderly. <i>Current Atherosclerosis Reports</i> , <b>2014</b> , 16, 420	6	20
97	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , <b>2021</b> , 166, 105499	10.2	20
96	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , <b>2018</b> , 272, 20-25	3.2	19
95	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , <b>2019</b> , 39, e1-e8	1.7	18
94	A review of gene- and cell-based therapies for familial hypercholesterolemia. <i>Pharmacological Research</i> , <b>2019</b> , 143, 119-132	10.2	18
93	Effects of resistant starch on glycemic control, serum lipoproteins and systemic inflammation in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2020</b> , 60, 3172-3184	11.5	18
92	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , <b>2013</b> , 66, 53.e1-53.e46	1.5	17
91	The effects of -3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial. <i>British Journal of Nutrition</i> , <b>2020</b> , 123, 792-799	3.6	17
90	Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , <b>2017</b> , 31, 197-208	3.9	16
89	Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19. <i>International Journal for Vitamin and Nutrition Research</i> , <b>2021</b> , 1-18	1.7	16

88	Cardiovascular disease (CVD) risk factors in older adults - Perception and reality. <i>Archives of Gerontology and Geriatrics</i> , <b>2015</b> , 61, 88-92	4	15
87	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 801-809	4.9	15
86	A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels. <i>Current Medicinal Chemistry</i> , <b>2016</b> , 23, 4490-4503	4.3	15
85	The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , <b>2020</b> , 34, 239-253	6.7	15
84	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , <b>2019</b> , 34, 247-258	12.1	15
83	Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 84-91	3.9	14
82	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , <b>2019</b> , 40, 336-344	9.5	14
81	The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis. <i>Biomolecules</i> , <b>2019</b> , 9,	5.9	13
80	The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , <b>2019</b> , 33, 2609-2621	6.7	13
79	Differences in risk factors for coronary heart disease in patients from continental and Mediterranean regions of Croatia. <i>Wiener Klinische Wochenschrift</i> , <b>2008</b> , 120, 684-92	2.3	13
78	Macrophage: A Key Therapeutic Target in Atherosclerosis?. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 3165-3174	3.3	13
77	Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. <i>Psychiatria Danubina</i> , <b>2007</b> , 19, 270-81	1.8	12
76	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. <i>Current Atherosclerosis Reports</i> , <b>2019</b> , 21, 14	6	11
75	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. <i>Cancer Cell International</i> , <b>2020</b> , 20, 560	6.4	11
74	The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Lipids in Health and Disease</i> , <b>2020</b> , 19, 112	4.4	11
73	Mutation detection in Croatian patients with familial hypercholesterolemia. <i>Annals of Human Genetics</i> , <b>2013</b> , 77, 22-30	2.2	11
72	Clinical study on the effect of simvastatin on paraoxonase activity. <i>Arzneimittelforschung</i> , <b>2007</b> , 57, 647-53		11
71	The effects of saffron ( <i>Crocus sativus</i> L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. <i>Complementary Therapies in Medicine</i> , <b>2020</b> , 48, 102250	3.5	11



70	Medicinal plants and bioactive natural compounds as inhibitors of HMG-CoA reductase: A literature review. <i>BioFactors</i> , <b>2020</b> , 46, 906-926	6.1	11
69	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 1630-1636	3.9	11
68	Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins. <i>Croatian Medical Journal</i> , <b>2004</b> , 45, 333-7	1.6	11
67	The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	10
66	A comparison of European and US guidelines for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , <b>2015</b> , 26, 215-20	4.4	10
65	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1618-27	3.9	10
64	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , <b>2019</b> , 15, 1365-1374 <sup>2,9</sup>	2.9	10
63	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 33-43	3.9	10
62	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>BMJ Open</i> , <b>2019</b> , 8, e021508	3	10
61	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. <i>Korean Circulation Journal</i> , <b>2018</b> , 48, 1097-1119	2.2	10
60	Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment. <i>Plant Foods for Human Nutrition</i> , <b>2020</b> , 75, 307-315	3.9	9
59	Diabetic dyslipidemia or Qdiabetes lipidusQ. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 341-8	2.5	9
58	The effects of L-carnitine supplementation on indicators of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , <b>2020</b> , 19, 1879-1894	2.5	9
57	Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. <i>Croatian Medical Journal</i> , <b>2005</b> , 46, 984-9	1.6	9
56	The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , <b>2020</b> , 38, 43-49	1.3	8
55	Guñ de prñtica clñica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciñ con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , <b>2014</b> , 67, 136.e1-136.e56	1.5	8
54	Prevalence of statin intolerance: a meta-analysis.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	8
53	Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. <i>Cancer Cell International</i> , <b>2021</b> , 21, 388	6.4	8

52	Novel Experimental Agents for the Treatment of Hypercholesterolemia. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 91-100	3	8
51	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , <b>2020</b> , 155, 104719	10.2	7
50	A systematic review and meta-analysis: The effects of probiotic supplementation on metabolic profile in patients with neurological disorders. <i>Complementary Therapies in Medicine</i> , <b>2020</b> , 53, 102507	3.5	7
49	Effects of statins on preeclampsia: A systematic review. <i>Pregnancy Hypertension</i> , <b>2021</b> , 23, 123-130	2.6	7
48	Postmarketing nutriviigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , <b>2021</b> , 17, 856-863	2.9	7
47	Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 575877	5.6	6
46	Fetal toxicity associated with statins: A systematic review and meta-analysis. <i>Atherosclerosis</i> , <b>2021</b> , 327, 59-67	3.1	6
45	Statin therapy and sex hormones. <i>European Journal of Pharmacology</i> , <b>2021</b> , 890, 173745	5.3	6
44	Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 820260	5.4	6
43	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. <i>International Journal of Cardiology</i> , <b>2021</b> , 322, 227-232	3.2	5
42	Recomendações Europeias para a prevenção da doença cardiovascular na prática clínica (versão de 2012). <i>Revista Portuguesa De Cardiologia</i> , <b>2013</b> , 32, 553.e1-553.e77	1	4
41	Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <i>Mediators of Inflammation</i> , <b>2022</b> , 2022, 8732360	4.3	4
40	The effects of L-carnitine supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. <i>EXCLI Journal</i> , <b>2019</b> , 18, 631-643	2.4	4
39	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	4
38	Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , <b>2020</b> , 177, 25-52	2.9	4
37	Quercetin as a Novel Therapeutic Approach for Lymphoma. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2021</b> , 2021, 3157867	6.7	4
36	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. <i>Current Medicinal Chemistry</i> , <b>2021</b> , 28, 6066-6081	4.3	4
35	Rice policosanol does not have any effects on blood coagulation factors in hypercholesterolemic patients. <i>Collegium Antropologicum</i> , <b>2007</b> , 31, 1061-4	0.1	4

34	Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 45, 102381	4	3
33	Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	3
32	Polypill is not a vaccine-like solution for primary cardiovascular disease prevention in all parts of the world. <i>Journal of Epidemiology and Community Health</i> , <b>2013</b> , 67, 981-2	5.1	3
31	Statins for primary prevention: problems with cardiovascular-risk estimation?. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 547	14.8	3
30	Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.. <i>Cardiovascular Therapeutics</i> , <b>2022</b> , 2022, 8129513	3.3	3
29	The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 3266-3281	3.3	3
28	Similarities and differences between European and United States guidelines for the management of dyslipidaemias. <i>Kardiologia Polska</i> , <b>2015</b> , 73, 471-7	0.9	3
27	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 2015-2023	1.9	3
26	The effects of catechin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2020</b> , 60, 2369-2378	11.5	3
25	Resveratrol and cardiac fibrosis prevention and treatment. <i>Current Pharmaceutical Biotechnology</i> , <b>2021</b> ,	2.6	3
24	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , <b>2018</b> , 21, 1334-1336	1.2	3
23	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> ,	10.3	3
22	The effects of omega-3 fatty acids supplementation on metabolic status in pregnant women: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , <b>2020</b> , 19, 1685-1699	2.5	2
21	Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: A meta-analysis of randomized clinical trials. <i>Clinical Nutrition ESPEN</i> , <b>2020</b> , 37, 24-33	1.3	2
20	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
19	The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 682352	5.4	2
18	Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. <i>Journal of Cardiovascular Development and Disease</i> , <b>2021</b> , 8,	4.2	2
17	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. <i>Atherosclerosis</i> , <b>2022</b> , 348, 25-35	3.1	2

16	Impact of Treating Dyslipidemia on Cardiovascular Events <b>2011</b> , 238-246		1
15	Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. <i>Clinical Lipidology</i> , <b>2010</b> , 5, 325-328		1
14	Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity. <i>Arzneimittelforschung</i> , <b>2005</b> , 55, 271-275		1
13	The role of statins in lung cancer.. <i>Archives of Medical Science</i> , <b>2022</b> , 18, 141-152	2.9	1
12	In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). <i>Chemico-Biological Interactions</i> , <b>2021</b> , 345, 109528	5	1
11	Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 61, 325-336	11.5	1
10	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , <b>2021</b> , 2021, 9661752	4.3	1
9	A pilot Croatian survey of risk factor (CRO-SURF) management in patients with cardiovascular disease. <i>Collegium Antropologicum</i> , <b>2012</b> , 36, 369-73	0.1	1
8	The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair. <i>Heart Failure Reviews</i> , <b>2020</b> , 1	5	0
7	At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products. <i>Journal of Medical Economics</i> , <b>2020</b> , 23, 1193-1195	2.4	0
6	Impact of Bariatric Surgery on Pulse Wave Velocity as a Measure of Arterial Stiffness: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , <b>2021</b> , 31, 4461-4469	3.7	0
5	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis.. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2021</b> , 2021, 4136071	6.7	0
4	Statistical vs clinical significance: A matter of debate for orlistat treatment. <i>Pharmacological Research</i> , <b>2017</b> , 124, 158-159	10.2	
3	Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome - A case report.. <i>Transfusion and Apheresis Science</i> , <b>2021</b> , 103346	2.4	
2	Oxidative stress mediated cytogenotoxicological effects of phytol in wistar albino rats. <i>Advances in Traditional Medicine</i> ,1	1.4	
1	The Effects of N-acetylcysteine on Inflammatory Markers and Homocysteine: A Systematic Review and Meta-analysis of Randomized Controlled Trials <b>2020</b> , 26, 214-224		